Physician profile
Christopher Chen
NPI 1700312840
$20,474.75
in general payments reported to CMS, 2019-2025
9 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $176 · 2023: $59.67 · 2024: $16K · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Consulting Fee: $3,239 · Food and Beverage: $2,664 · Travel and Lodging: $1,433 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,500.00 |
| Consulting Fee | $3,239.00 |
| Food and Beverage | $2,663.81 |
| Travel and Lodging | $1,432.78 |
| Education | $231.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,515.31 | 2021-2024 | |
| Medtronic, INC. | $5,798.11 | 2024-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Selectsecure |
| Impulse Dynamics (USA) INC. | $3,539.00 | 2025 | |
| Abbott Laboratories | $3,079.02 | 2021-2024 | Ensite Precision, Ensite |
| Biosense Webster, INC. | $332.99 | 2024-2025 | Carto 3, Qdot Micro Catheter |
| Abiomed | $89.34 | 2023-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $58.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.85 | 2025 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $13.97 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.